Acrobiosystems for English
icon_bulk_orderBulk inquiry/Quick order
There is no goods in the shopping cart !
A B C D E F G H I J K L M N O P Q R S T U V W X Y Z 0-9
Your Position: Home > CD4


Brief Information

Name:T-cell surface antigen CD4
Target Synonym:CD4mut,CD4 Antigens,T-cell surface antigen T4/Leu-3,T-cell surface glycoprotein CD4,CD4,CD4 Molecule,CD4 Antigen (P55),CD4 Receptor,CD4 Antigen
Number of Launched Drugs:1
Number of Drugs in Clinical Trials:23
Lastest Research Phase:Approved

Product ListCompare or Buy

ACRO Quality

Part of Bioactivity data

CD4-HP2E3-Cell-based assay
FACS assay shows that recombinant Biotinylated FACS

5e5 of anti-CD4 CAR-293 cells were stained with 100 μL of 1:50 dilution (2 μL stock solution in 100 μL FACS buffer) of PE-Labeled Human CD4, His Tag (Cat. No. CD4-HP2E3) and negative control protein respectively. PE signal was used to evaluate the binding activity (QC tested).

CD4-HF2H7-Cell-based assay

2e5 of CD4-CAR-293 cells were stained with 100 μL of 0.3 μg/mL of FITC-Labeled Human CD4, His Tag (Cat. No. CD4-HF2H7) and negative control protein respectively, FITC signal was used to evaluate the binding activity (QC tested).


Immobilized Ibalizumab at 1 μg/mL (100 μL/well) can bind FITC-Labeled Human CD4, His Tag (Cat. No. CD4-HF2H7) with a linear range of 0.01-0.156 μg/mL (QC tested).

CD4 MALS images

The purity of Biotinylated Rhesus macaque CD4,His,Avitag (Cat. No. CD4-R82E3) is more than 90% and the molecular weight of this protein is around 43-53 kDa verified by SEC-MALS.

Synonym Name



Cluster of Differentiation 4 (CD4) is also known as T-cell surface antigen T4/Leu-3 (LEU-3) and CD4mut, is a single-pass type I  membrane glycoprotein,and is a member of the immunoglobulin superfamily. CD4 expressed on the surface of T helper cells, monocytes, macrophages, and dendritic cells. It has four immunoglobulin domains (D1 to D4) that are exposed on the extracellular surface of the cell: D1 and D3 resemble immunoglobulin variable (IgV) domains. D2 and D4 resemble immunoglobulin constant (IgC) domains. CD4 is a co-receptor that assists the T cell receptor (TCR) with an antigen-presenting cell. Using its portion that resides inside the T cell, CD4 amplifies the signal generated by the TCR by recruiting an enzyme, known as the tyrosine kinase lck, which is essential for activating many molecules involved in the signaling cascade of an activated T cell. CD4 also interacts directly with MHC class II molecules on the surface of the antigen-presenting cell using its extracellular domain. The extracellular domain adopts an immunoglobulin-like beta-sandwich with seven strands in 2 beta sheets, in a Greek key topology. CD4 has also been shown to interact with SPG21, Lck and Protein unc-119 homolog. CD4 is a primary receptor used by HIV-1 to gain entry into host T cells. HIV infection leads to a progressive reduction of the number of T cells possessing CD4 receptors. Therefore, medical professionals refer to the CD4 count to decide when to begin treatment for HIV-infected patients.

Clinical and Translational Updates

Related Molecule

Public Drug Information

Name Research Code Research Phase Company First Brand Name First Approved Country First Indication First Approved Company First Approved Date Indications Clinical Trials
Ibalizumab Hu5A8; TMB-355; TNX-355; 5AB Approved Biogen Inc 特罗格佐, Trogarzo United States HIV Infections Theratechnologies Inc 2018-03-06 HIV Infections Details

Clinical Drug Information

Name Research Code Research Phase Company Indications Clinical Trials
Semzuvolimab dB4; UB-421; mAb-B4 Phase 3 Clinical United Biomedical Inc HIV Infections Details
ITV 1(Nonindustrial source) ITV-1 Phase 3 Clinical Synexa Life Sciences, Immunotech Laboratories HIV Infections Details
RB-0003 RB-0003; BNT-111 Phase 2 Clinical Biontech Se, Tron Melanoma Details
VRC-01-LS VRC-HIVMAB-080-00-AB; VRC-01-LS Phase 2 Clinical National Institute Of Allergy And Infectious Diseases (Niaid) HIV Infections Details
VRC-07-523 VRC-07-523-L S; VRC-HIVMAB075-00-AB; VRC-HIVMAB-075 -00-AB; VRC-07-523; TMB-380 Phase 2 Clinical National Institute Of Allergy And Infectious Diseases (Niaid), Taimed Biologics Inc Acquired Immunodeficiency Syndrome; HIV Infections; Retroviridae Infections; Sexually Transmitted Diseases, Viral; HIV Seropositivity Details
GEN-009 GEN-009 Phase 2 Clinical Genocea Biosciences Inc Skin Melanoma; Carcinoma, Renal Cell; Squamous Cell Carcinoma of Head and Neck; Carcinoma, Transitional Cell; Carcinoma, Non-Small-Cell Lung Details
Tregalizumab hB-F5; BT-061 Phase 2 Clinical Biotest Pharma Gmbh Drug Hypersensitivity; Arthritis, Rheumatoid; Psoriasis; Asthma Details
MVA-EL MVA-EBNA1/LMP2 Phase 2 Clinical Chinese University Of Hong Kong (Cuhk), Cancer Research UK Head and Neck Neoplasms; Stomach Neoplasms; Nasopharyngeal Neoplasms; Lymphoproliferative Disorders; Epstein-Barr Virus Infections; Lymphoma Details
VRC-HIVMAB091-00-AB N6LS; Z258‐N6LS; VRC-HIVMAB091-00-AB Phase 2 Clinical National Institute Of Allergy And Infectious Diseases (Niaid) HIV Infections Details
IMCY-0141 IMCY-0141 Phase 2 Clinical Imcyse Sa Multiple Sclerosis, Relapsing-Remitting Details
Autologous Regulatory Т-cell Therapy Phase 2 Clinical Institute Of Biophysics And Cell Engineering Of National Academy Of Sciences Of Belarus Scleroderma, Systemic Details
CD4-directed chimeric antigen receptor engineered T-cells (Icell Gene) CD4CAR (Icell Gene) Phase 1 Clinical Stony Brook University School Of Medicine, Icell Gene Therapeutics (Int'L) Ltd, University Of Louisville Leukemia, Myelomonocytic, Chronic; Lymphoma, T-Cell; Leukemia, T-Cell Details
T-allo-10 T-allo-10 Phase 1 Clinical Stanford University Hematologic Diseases; Leukemia; Graft vs Host Disease; Hodgkin Disease; Myelodysplastic Syndromes; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Leukemia, Myeloid, Acute; Lymphoma, Non-Hodgkin Details
Anti-CD4 CAR T-cell therapy (University of Pennsylvania) CAR-C34ZFN Phase 1 Clinical University Of Pennsylvania HIV Infections; HIV Seropositivity Details
10E8.4/iMab (Aaron Diamond AIDS Research Center) TMB-370 Phase 1 Clinical Aaron Diamond Aids Research Center For The City Of New York, Inc HIV Infections Details
CALRLong36 peptide (Herlev Hospital) Phase 1 Clinical Herlev Hospital Myeloproliferative Disorders Details
VRC-HIVMAB060-00-AB VRC-HIVMAB060-00-AB; VRC01 Phase 1 Clinical National Institute Of Allergy And Infectious Diseases (Niaid) HIV Infections Details
VRC-HIVMAB0115-00-AB Phase 1 Clinical National Institute Of Allergy And Infectious Diseases (Niaid) HIV Infections; HIV Seropositivity Details
SCRI-E2CAR_EGFRtv1 SCRI-E2CAR_EGFRtv1 Phase 1 Clinical Umoja BioPharma Inc Osteosarcoma Details
CD4^LVFOXP3 Treg-like cell therapy CD4^LVFOXP3 Phase 1 Clinical Stanford University Polyendocrinopathies, Autoimmune Details
TMB-365 TMB-365 Phase 1 Clinical Taimed Biologics Inc HIV Infections Details
LB-1901 LB1901; LB-1901 Phase 1 Clinical Nanjing Legend Biotechnology Co Ltd Lymphoma, T-Cell, Peripheral; Lymphoma, T-Cell; Lymphoma, T-Cell, Cutaneous Details
IT-1208 (Kyowa Hakko Kirin) IT-1208 Phase 1 Clinical Kyowa Hakko Kirin Co Ltd Neoplasms Details

This web search service is supported by Google Inc.

Call us
Call us
North America:
+1 800-810-0816 (Toll Free)
Asia & Pacific:
+86 400-682-2521
+1 888-377-6111
1 Innovation Way, Newark, DE 19711, USA

Leave a message